Skip to main content

Industry Partners

Translational Medicine

At the North Carolina State University College of Medicine, we move our research from the bench to the patient. Our researchers span a number of research strengths including regenerative medicine, infectious disease, biological barriers, genetics, neurosciences and computational research.

 

 

 

 

Some of our bench to patient work has included the following studies:

 

  • A study on the impact of drug enrofloxacin on cattle finds dosing regimens in which antimicrobial concentrations rapidly achieve pharmacodynamic targets and are quickly eliminated from the gastrointestinal tract minimize the effect on fecal microbiota.

The research, published in Frontiers in Microbiology, shows that quick elimination mitigates long-term impacts on fecal E. coli resistance, a major finding since intestinal concentrations of antimicrobials that select for resistance in the fecal bacteria of cattle is not well understood.

The study is co-authored by Derek Foster, Mark Papich, Timo Prange, Benjamin Callahan, Casey Theriot, Megan Jacob and Kaitlyn Ferguson.

Read the study here.

 

  • A study into the anti-inflammatory effects of misoprostol on horses shows that the medication is rapidly absorbed following oral administration.

Misoprostol is anecdotally used to treat and prevent nonsteroidal anti-inflammatory drug-induced equine gastrointestinal injuries. The study, co-authored by Emily Martin, Sam Jones and Jenna Marie Schirmer and published in the Equine Veterinary Journal, sheds light on the pharmacokinetics and anti-inflammatory impact of misoprostol, which are not well understood.

Read the study here.

  • An investigation into extended-release levetiracetam provides insight into proper dosing and mechanisms of the antiepileptic drug for dogs.

The study, co-authored by Karen Muñana, Mark Papich, Julie Nettifee and Arturo Otamendi and published in the Journal of Veterinary Internal Medicine, looks into the pharmacokinetics of the drug, also known as LEV-XR, when administered alone and with phenobarbital or zonisamide.

LEV-XR has gained acceptance as a treatment for canine epilepsy, but no studies have previously evaluated its disposition in dogs with the condition. Among the conclusions of the research: considerable pharmacokinetic variation exists in LEV-XR in dogs treated with a common dosing regimen, and drug monitoring may help determine the best dose of the medication in individual dogs.

Read the study here.